KeyBanc Capital Markets raised the price target for the Catalent Inc. (NYSE:CTLT) stock from “an Overweight” to “a Sector weight”. The rating was released on December 19, 2022, according to finviz. The research report from BofA Securities has downgraded the stock from Buy to Neutral, with a price target set at $60. The stock was initiated by Barclays, who disclosed in a research note on December 16, 2021, to Overweight and set the price objective to $160. In their research brief published December 10, 2020, KeyBanc Capital Markets analysts upgraded the Catalent Inc. stock from Sector Weight to Overweight with a price target of $120.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Catalent Inc. (NYSE:CTLT) raised 6.35% to close Monday’s market session at $52.59, higher as compared to yesterday’s close. The stock price fluctuated between $49.01 and $52.67 throughout the trading session with the volume trading being 3373036 shares, which represented a significant variation when compared to the three months average volume of 3.34 million shares. The firm’s stock price fluctuated 7.15% within the last five trades and 18.55% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -51.13% in the last 6 months and -22.97% was subtracted to its value over the previous 3 months. CTLT stock is trading at a margin of 12.96%, 14.25% and -36.22% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, CTLT deals in the Healthcare domain. The stock is trading -54.40 percent below its 52-week high and 29.25 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -40.9. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Catalent Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 14.10 percent and the profit margin is 8.70 percent, and the company has reported a gross margin of 32.60 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $9.43 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Catalent Inc. (NYSE:CTLT) is 22.49. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 14.35. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 1.96 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 2.01, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Boerman Manja, the Pres. BioModalities Division at Catalent Inc. (CTLT) has sold 780 shares of firm on Dec 05 at a price of $51.70 against the total amount of $40326.0. In another inside trade, Grippo Michael J, SVP, Strategy & Corp. Dev. of Catalent Inc. (NYSE:CTLT) sold 2,451 shares of the firm on Oct 31 for a total worth of $0.16 million at a price of $65.83. An inside trade which took place on Oct 10, Pres. Pharma Prod Delivery Div of Catalent Inc. Hawkeswood Thomas W sold 930 shares of firm against total price of $72038.0 at the cost of $77.46 per share.